Trial reportAmerican journal of respiratory and critical care medicine2021
Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Trial report in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial.British journal of cancer · 2025Trial
- Neural-tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies.Biomarker research · 2026Review
- Neural regulation in lung cancer: from mechanisms to new therapeutic perspectives.Clinical and experimental medicine · 2026Review
- Physiological mechanisms and therapeutic targets in chronic cough.Physiological reports · 2026Review
- Innovative Tools and Perspectives in Cough Management: Cancer and Cough.Tuberculosis and respiratory diseases · 2026Review
- Review
- Unraveling the neuro-immune axis in cough hypersensitivity: from pathogenesis to synergistic management.Frontiers in medicine · 2026Review
- Observational
- Cough in idiopathic pulmonary fibrosis: what is new.Breathe (Sheffield, England) · 2025Article
- Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough.Drugs · 2024Review
- Advances in the research and application of neurokinin-1 receptor antagonists.Journal of Zhejiang University. Science. B · 2024Review
- The Therapeutic Landscape in Chronic Cough.Lung · 2024Review
- TRPM8 inhibits substance P release from primary sensory neurons via PKA/GSK-3beta to protect colonic epithelium in colitis.Cell death & disease · 2024Article
- Patient's experiences of coughing after lung cancer surgery: A multicenter qualitative study.Cancer medicine · 2024Article
- Review
- Review
- The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.International journal of molecular sciences · 2023Review
- Efficacy of gefapixant, a P2XThe Journal of international medical research · 2023Article
- Measuring cough: what really matters?Journal of thoracic disease · 2023Review
- Cough hypersensitivity and chronic cough.Nature reviews. Disease primers · 2022Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.